Tilray Stock Forecast, Price & News

Tilray's stock was trading at $7.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TLRY shares have decreased by 8.6% and is now trading at $6.48.
View which stocks have been most impacted by COVID-19.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 1 sell rating, 12 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Tilray.

Tilray is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Tilray.

Tilray Inc (NASDAQ:TLRY) announced its earnings results on Monday, August, 10th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.38. The business earned $50.41 million during the quarter, compared to analysts' expectations of $54.99 million. Tilray had a negative net margin of 259.60% and a negative return on equity of 77.77%. The company's quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.32) earnings per share.
View Tilray's earnings history.

15 analysts have issued twelve-month target prices for Tilray's shares. Their forecasts range from $4.00 to $31.00. On average, they expect Tilray's share price to reach $12.73 in the next year. This suggests a possible upside of 96.4% from the stock's current price.
View analysts' price targets for Tilray.

Tilray saw a increase in short interest in September. As of September 30th, there was short interest totaling 23,830,000 shares, an increase of 39.3% from the September 15th total of 17,110,000 shares. Based on an average daily trading volume, of 6,410,000 shares, the short-interest ratio is presently 3.7 days.
View Tilray's Short Interest.

Some companies that are related to Tilray include Cronos Group (CRON), USANA Health Sciences (USNA), Aphria (APHA), Aphria (APHA), Aurora Cannabis (ACB), Canopy Rivers (RIV), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), Charlie's (CHUC), Happiness Biotech Group (HAPP), Mannatech (MTEX), FSD Pharma (HUGE), Sundial Growers (SNDL) and Glucose Health (GLUC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Square (SQ).

(TLRY) raised $135 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company acted as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TLRY stock can currently be purchased for approximately $6.48.

Tilray has a market capitalization of $824.11 million and generates $166.98 million in revenue each year. The company earns $-321,170,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Tilray employs 1,646 workers across the globe.

The official website for Tilray is www.tilray.com.

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The company can be reached via phone at 206-432-9325.